A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512): stage 1 results

被引：0
|
作者：
Lee, Elizabeth [1 ]
Zhou, Yinglu [2 ]
Hendrickson, Andrea Wahner [3 ]
Fleming, Gini [4 ]
Konstantinopoulos, Panagiotis [1 ]
Krasner, Carolyn [1 ]
Stover, Elizabeth [1 ]
Horowitz, Neil [5 ]
Porter, Rebecca [1 ]
Wright, Alexi [1 ]
Matulonis, Ursula [1 ]
Xiong, Niya [2 ]
Sawyer, Hannah [1 ]
Tayob, Nabihah [2 ]
Liu, Joyce [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Data Sci, Boston, MA 02115 USA
[3] Mayo Clin, Comprehens Canc Ctr, Rochester, MN 55906 USA
[4] Univ Chicago, Med Oncol, Chicago, IL USA
[5] Brigham & Womens Hosp, Div Gynecol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB009/#156
引用
收藏
页码：A11 / A12
页数：2
相关论文
共 50 条
  • [31] A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Llovet, J.
    Shepard, K. V.
    Finn, R. S.
    Ikeda, M.
    Sung, M.
    Baron, A. D.
    Kudo, M.
    Okusaka, T.
    Kobayashi, M.
    Kumada, H.
    Kaneko, S.
    Pracht, M.
    Mamontov, K.
    Meyer, T.
    Mody, K.
    Kubota, T.
    Saito, K.
    Siegel, A. B.
    Dubrovsky, L.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kralijevic, Silvija
    Ikezawa, Hiroki
    Siegel, Abby B.
    Kumada, Hiromitsu
    Okusaka, Takuji
    CANCER RESEARCH, 2019, 79 (13)
  • [33] A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
    Makker, Vicky
    Rasco, Drew W.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Li, Di
    Schmidt, Emmett V.
    Shumaker, Robert Charles
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
    Ngoi, N. Y.
    Lee, J-Y.
    Lim, Y. W.
    Lim, D.
    Thian, Y. L.
    Gopinathan, A.
    Lim, S. E.
    Low, J.
    Ng, J.
    Tong, P.
    Zhu, J.
    Tai, B. C.
    Lee, Y. J.
    Park, J.
    Kim, J-W.
    Kim, B-G.
    Tan, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1584 - S1584
  • [35] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    Di Simone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett, V
    Perini, Rodolfo F.
    Kubiak, Peter
    Smith, Alan D.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
    Taylor, Matthew H.
    Rasco, Drew W.
    Brose, Marcia S.
    Vogelzang, Nicholas J.
    Richey, Stephen Lane
    Cohn, Allen Lee
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Guo, Matthew
    Shumaker, Robert Charles
    Schmidt, Emmett V.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Phase II trial of capecitabine and cisplatin in advanced, persistent or recurrent carcinoma of the cervix
    Errihanni, H.
    Elghissassi, I.
    M'rabti, H.
    Sbitti, Y.
    Boutayeb, S.
    Afqir, S.
    Bensouda, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, C-H.
    Shah, A. Y.
    Makker, V.
    Taylor, M. H.
    Shaffer, D.
    Hsieh, J. J.
    Cohn, A. L.
    DiSimone, C.
    Pinto Marin, A.
    Rasco, D. W.
    Ribe, S. G.
    Richards, D. A.
    Stepan, D. E.
    Dutcus, C. E.
    Wu, J.
    Schmidt, E. V.
    Perini, R. F.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 483 - +
  • [39] Phase II Trial of Capecitabine and Cisplatin in Advanced, Persistent, or Recurrent Carcinoma of the Cervix
    Errihani, Hassan
    M'rabti, Hind
    Ismaili, Nabil
    Inrhaoun, Hanane
    Elghissassi, Ibrahim
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (02) : 373 - 377
  • [40] Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial
    Aronson, L.
    Thijssen, B.
    Lopez-Yurda, M.
    Koole, S.
    van der Leest, P.
    Leon-Castillo, A.
    Harkes, R.
    Seignette, I.
    Sanders, J.
    Alkemade, M.
    Kemper, I.
    Holtkamp, M.
    Mandjes, I.
    Broeks, A.
    Lahaye, M.
    Rijlaarsdam, M.
    Van Den Broek, D.
    Horlings, H. M.
    van Driel, W.
    Sonke, G. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S581 - S581
12345